Last updated on January 2019

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Brief description of study

The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome.

Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Detailed Study Description

A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).

Clinical Study Identifier: NCT03690206

Contact Investigators or Research Sites near you

Start Over

Senior Clinical Trial Manager

H pital Beaujon
Clichy, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.